Clinical Trial Evidence: What the Research Shows Phase 2 trial data published in the NEJM (2023) showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, alongside improvements in blood pressure, lipid profiles, and fasting glucose, though Phase 3 results are still awaited
(1) Not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease
Unknown long-term interactions The most honest assessment of combining tesamorelin and retatrutide is simply this: nobody knows what happens
BOX 7-1 Lesion Characteristics in Nails That Should Raise a Red Flag Location: Single digit, thumb, or great toe nails Appearance: Fast growth, longitudinal melanonychia, band width more than 3-5 mm Hutchinsons Sign: Periungual pigmentation of skin Nail Dystrophy: Notch in free distal nail margin, surface irregularity, oozing, or bleeding lesion similar to ingrown nail Melanonychia striata Brown longitudinal stria (plural is striae) that occurs in the nail is called melanonychia striata